Prognostic Value of Tumor Regression Grading in Patients Treated With Neoadjuvant Chemotherapy Plus Surgery for Gastric Cancer.

There was a trend toward improving recurrence-free survival in patients receiving the oxaliplatin-based regimen; however, this trend did not reach statistical significance (48.4 vs 23 months, respectively; p=0.178) ( Figure 2B ).

also in 111,027 other papers

The oxaliplatin-based regimen for patients with neoadjuvant chemotherapy showed a trend toward improving recurrence-free survival ( Figure 3B ); however, this result did not reach statistical significance when compared to the nonoxaliplatin-based regimen (53.3 versus 42.8 months, p=0.14, respectively).

also in 53,322 other papers